Literature DB >> 6702416

Increased fragility of erythrocytes from amyotrophic lateral sclerosis (ALS) patients provoked by mechanical stress.

L O Ronnevi, S Conradi.   

Abstract

Erythrocytes from patients with amyotrophic lateral sclerosis (ALS) and controls were suspended in an electrolyte-substrate medium and subjected to mechanical stress by centrifugation under standardized conditions. Subsequent spectrophotometric analysis of the medium disclosed a significantly higher degree of haemolysis in samples from ALS-patients than from controls. The observation gives further evidence for the existence of an abnormality of the red cells in the disease. The nature and possible significance of this abnormality in relation to the pathogenesis of ALS is as yet unknown, but notably there was no significant correlation between the degree of cell abnormality as manifested by haemolysis and the duration of the disease in the individual patient.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6702416     DOI: 10.1111/j.1600-0404.1984.tb07775.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  3 in total

1.  Complement alterations in the CSF of patients with amyotrophic lateral sclerosis.

Authors:  P Annunziata
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-03       Impact factor: 10.154

2.  ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia.

Authors:  William R Swindell; Colin P S Kruse; Edward O List; Darlene E Berryman; John J Kopchick
Journal:  J Transl Med       Date:  2019-05-22       Impact factor: 5.531

3.  Identification of let-7f and miR-338 as plasma-based biomarkers for sporadic amyotrophic lateral sclerosis using meta-analysis and empirical validation.

Authors:  Narges Daneshafrooz; Mohammad Taghi Joghataei; Mehdi Mehdizadeh; Afagh Alavi; Mahmood Barati; Bahman Panahi; Shahram Teimourian; Babak Zamani
Journal:  Sci Rep       Date:  2022-01-26       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.